Nymox provided an update on the Company's Phase 3 U.S. trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The most recent Safety Monitoring Committee meeting was favorable and indicated no significant safety concerns for the three ongoing U.S. Phase 3 trials to date. NX-1207 has been shown to improve the signs and symptoms of BPH, producing improvements which reached statistical significance compared to double-blinded placebo and study controls.
- benign prostatic hyperplasia